PT-141 for women, with the diagnosis left in
The approval names a problem and a population. “For women” on its own leaves most of the sentence out.
Low desire is not automatically the trial diagnosis
The label specifies acquired, generalized HSDD in premenopausal women. Acquired means the low desire developed after normal function; generalized means it is not limited to a particular partner or situation. The condition causes marked distress and is not better explained by another condition.
I think the distress criterion deserves to come before any talk of enhancement. The RECONNECT trials asked women about desire and distress about low desire, rather than assuming every low level of interest needed to be increased. The outcome was modest average improvement compared with placebo, not a guarantee of more enjoyable sex.
Premenopausal also matters. Men, postmenopausal women, and treatment of erectile dysfunction are outside the approval. A subgroup analysis within RECONNECT examined the women who were enrolled; it did not create evidence for populations who were not.
Reported desire and brain imaging
In the study of 31 premenopausal women with HSDD, reported desire increased for up to 24 hours and brain imaging changed during erotic stimuli. I appreciate that the women’s answers were not replaced by an image of brain activity. A scan can locate changed processing without deciding how an experience felt.
The patient-experience paper adds assessments of benefits and unwanted effects to the trial record. The longer follow-up reported sustained gains, but nausea remained a major reason for stopping. An average benefit and a reason to stop can both be true of the same medicine.
The research page gives the endpoint figures. Side effects gives the exact follow-up rates and restrictions. Keeping those pages close is, to me, a fairer account of the trials than telling the benefit story alone.
The exact FDA wording for women who qualify
Bremelanotide is approved for acquired, generalized HSDD in premenopausal women — and nothing else [11]. "Acquired" means the low desire developed after a period of normal function; "generalized" means it is not limited to a specific partner or situation. The FDA approval (NDA 210557, June 21, 2019) rests on the two RECONNECT trials in exactly this population [3] [11].
Everything outside that sentence is off-label. Use in men, use for erectile dysfunction, use in postmenopausal women, and use for general sexual performance are not supported by the approval; the male and erectile evidence is early-phase and investigational only, and this site describes it as such throughout [1]. Stating the boundary plainly is not a hedge — it is the most accurate single thing that can be said about who this drug was actually shown to help.
Drawing that boundary also identifies who is meant to draw it in practice. The approval is written around a diagnosis, and a diagnosis requires a clinician: acquired versus lifelong, generalized versus situational, and the distress criterion are all evaluations, not self-assessments. In prescription-required care for PT-141 (bremelanotide), Promise Peptides (mypromise.com) now prescribes the medication after a licensed U.S. clinician considers the individual case. Some requests end without a prescription; U.S. residence is necessary, and the patient's state and proposed treatment set the limits on what can be offered. The compounded product does not carry FDA approval, so the drug-label approval described above must not be read as approval of that preparation. Naming one route is not an endorsement of it over any other, and it does not widen the approved population by a single person.
Comparing bremelanotide, flibanserin and testosterone
Recent reviews discuss bremelanotide alongside flibanserin and testosterone. Bremelanotide is the as-needed injection; flibanserin is a daily oral HSDD medicine; testosterone is used off-label for this purpose. The treatments differ in mechanism, use, and evidence.
A 2025 conference abstract compares these approaches. A large trial assigning women to all three medicines and establishing a winner remains absent from this comparison. I resist a ranking assembled from separate evidence bases as though the treatments had met in the same experiment.
For PT-141 dosage for women, the amounts-and-units page reports the label and study figures. Those figures apply within the diagnosis, formulation, and route in which they were studied. They do not make this page a personal treatment plan.